CABA vs CRSP
CABA: Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with complex autoimmune diseases. CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs.
Side-by-side fundamentals
| Metric | CABA | CRSP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.75 | $47.24 | |
| Market cap as of 2026-07-23 | $449M | $4.6B | |
| PEG as of 2026-07-23 | n/a | -0.21 | |
| Net margin as of 2026-07-23 | n/a | -13856.5% | |
| Operating margin as of 2026-07-23 | n/a | -15754.2% | |
| ROE as of 2026-07-23 | -131.6% | -30.9% | CRSP higher |
| ROA as of 2026-07-23 | -96.5% | -24.5% | CRSP higher |
| Debt / equity as of 2026-07-23 | 0.23 | 0.32 | CABA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -89.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +43.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 3.27 | 1.77 | |
| 1-year return as of 2026-07-22 close | +72.0% | -26.3% | CABA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.